Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

Shares of Aquestive Therapeutics, Inc. ($AQST) traded flat early on Thursday, paring pre-market gains, amid a surge in retail chatter that pushed the stock into the top 10 trending tickers on Stocktwits. 

The company reported positive topline results from its Oral Allergy Syndrome (OAS) challenge study for its Anaphylm Sublingual Film. 

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. Food and Drug Administration (FDA).

Both the primary and secondary endpoints of the study were successfully met, with no significant differences observed between Anaphylm’s pharmacokinetics (PK) in subjects with and without allergen exposure. 

The Tmax, or time to maximum plasma concentration, remained at 12 minutes in both groups, while the Cmax, or maximum plasma concentration, was consistent between them. 

The drug was also found to be safe and well-tolerated, with all adverse events reported as mild or moderate, resolving without medical intervention.

On Stocktwits, retail sentiment for AQST surged into the ‘extremely bullish’ zone as of 9:30 am ET, accompanied by a sharp increase in message volume.

A little over a week ago, H.C. Wainwright raised its price target on Aquestive Therapeutics to $10 from $9, maintaining a ‘Buy’ rating. 

The analyst cited the company’s virtual investor day, which provided insights into its technology platform, product development, and long-term strategy.

Last month, Aquestive highlighted its Anaphylm Sublingual Film and AQST-108 Topical Gel during the event, both emerging from the company’s Adrenaverse epinephrine prodrug platform. 

CEO Daniel Barber expressed optimism about the company’s pipeline, mentioning that they had submitted a pre-NDA meeting request to the FDA for Anaphylm and were on track to report topline data from the OAS study.

Looking ahead, the company expects to hold a pre-Investigational New Drug (IND) meeting with the FDA in Q1 2025 and plans to begin a Phase 2 study for AQST-108, targeting alopecia areata, in the second half of 2025, pending FDA alignment.

Aquestive’s stock has gained over 160% year-to-date.

For updates and corrections email newsroom@stocktwits.com

Read next: Viking Therapeutics Stock Jumps After Q3 Earnings Beat: Retail Stays Cheerful

Share

·

Add us on